Latest Headlines

Latest Headlines

Australia's TGA registers Hospira's Inflectra

Australia's Therapeutic Good Administration has registered mAb biosimilar Inflectra (infliximab) from Hospira, the company said in a press release, noting it sets the stage for reimbursement under the country's Pharmaceutical Benefits Scheme.

Australian pharma group says high manufacturing costs killing drug exports

A pharma industry group in Australia has warned the government that it needs to do something to relieve the high costs of drug manufacturing in the country or continue to lose exports. 

Australia drug exports drop 30% as industry lobby group cites high manufacturing costs

Drug exports from Australia are down 30% in the past few years, trade figures show, with industry warning solutions to high manufacturing costs need to be addressed to compete or risk losing out to a growing market in Asia, the Sydney Morning Herald said.

More change ahead for Novogen as interim CEO Ross orders wide review of programs

Moving quickly to show investors a change of direction is ahead, Novogen acting Chief Executive Iain Ross announced a company-wide review of its preclinical programs less than a week after the abrupt departure of his predecessor, Graham Kelly.

Abrupt departure of Novogen CEO followed upbeat Anisina presentation

The abrupt departure of Australia's Novogen Chairman Graham Kelly this week came after the jointly listed Nasdaq and Australian Stock Exchange biotech presented details of an in vivo proof of concept study for anti-tropomyosin drug candidate Anisina in July in the U.S.

Australia's Novogen says CEO Kelly out, interim CEO Ross named

Australia's Novogen, listed on the Nasdaq and Australia Stock Exchange, said CEO Graham Kelly has resigned and that Iain Ross will take an acting role in the post until a permanent appointment is made.

Australia's Benitec buys out China partner for A$2.5M in hep B effort

Australia-listed Benitec Biopharma has bought the rights to the preclinical ddRNAi-based hepatitis B therapeutic program, Hepbarna, from partner China-based Biomics Biotechnologies, branching out as it looks to raise cash on the U.S. market.

Stormy Australia hearings on transfer pricing by drug firms invoke Sergeant Schultz

Multinational drug firms in Australia faced a string of barbs in hearings held by a Senate panel into transfer pricing that included a reference to a fictitious German World War II prison camp guard.

No artful tax dodging here, drug firms tell Australia transfer-price inquiry

We checked and everything is done correctly on our tax obligations, 9 drug companies said in separate submissions ahead of testimony on July 1 to an Australian Senate inquiry on tax avoidance.

Out with the old, reimburse the new: Merck's Frazier wades into Australia drug debate

Wading into what has become an "argy-bargy" political issue, Merck CEO Ken Frazier gave his two cents on why Australians miss out on new drugs.